Nanoparticles for Lymph Node-Directed Delivery
Lymph nodes are organs that control immune cells and provide a major pathway for primary tumors to metastasize. A nanoparticles-based strategy has several advantages that make it suitable for achieving effective lymphatic delivery. First, the size of nanoparticles can be tailored to meet a size rang...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/2/565 |
| _version_ | 1827755899696971776 |
|---|---|
| author | Jaeseong Lee Sungtaek Kang Hyeseon Park Jeong Gil Sun Eun Chae Kim Gayong Shim |
| author_facet | Jaeseong Lee Sungtaek Kang Hyeseon Park Jeong Gil Sun Eun Chae Kim Gayong Shim |
| author_sort | Jaeseong Lee |
| collection | DOAJ |
| description | Lymph nodes are organs that control immune cells and provide a major pathway for primary tumors to metastasize. A nanoparticles-based strategy has several advantages that make it suitable for achieving effective lymphatic delivery. First, the size of nanoparticles can be tailored to meet a size range appropriate for lymphatic migration. In addition, functionalized nanoparticles can target cells of interest for delivery of drugs or imaging probes. Existing lymph node contrast agents map all lymph nodes regardless of metastasis status; however, by using nanoparticles, it is possible to selectively target lymphatic metastases. Moreover, using functionalized nanoparticles, it is possible to specifically deliver anticancer drugs to metastatic lymph nodes. In this review, we introduce the use of nanoparticles for lymphatic mapping, in particular highlighting design considerations for detecting metastatic lymph nodes. Furthermore, we assess trends in lymph node-targeting nanoparticles in clinical practice and suggest future directions for lymph node-targeting nanoparticles. |
| first_indexed | 2024-03-11T08:16:34Z |
| format | Article |
| id | doaj.art-1af63f63aedc478db4c2510256091128 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T08:16:34Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-1af63f63aedc478db4c25102560911282023-11-16T22:41:38ZengMDPI AGPharmaceutics1999-49232023-02-0115256510.3390/pharmaceutics15020565Nanoparticles for Lymph Node-Directed DeliveryJaeseong Lee0Sungtaek Kang1Hyeseon Park2Jeong Gil Sun3Eun Chae Kim4Gayong Shim5School of Systems Biomedical Science and Integrative Institute of Basic Sciences, Soongsil University, Seoul 06978, Republic of KoreaSchool of Systems Biomedical Science and Integrative Institute of Basic Sciences, Soongsil University, Seoul 06978, Republic of KoreaSchool of Systems Biomedical Science and Integrative Institute of Basic Sciences, Soongsil University, Seoul 06978, Republic of KoreaSchool of Systems Biomedical Science and Integrative Institute of Basic Sciences, Soongsil University, Seoul 06978, Republic of KoreaSchool of Systems Biomedical Science and Integrative Institute of Basic Sciences, Soongsil University, Seoul 06978, Republic of KoreaSchool of Systems Biomedical Science and Integrative Institute of Basic Sciences, Soongsil University, Seoul 06978, Republic of KoreaLymph nodes are organs that control immune cells and provide a major pathway for primary tumors to metastasize. A nanoparticles-based strategy has several advantages that make it suitable for achieving effective lymphatic delivery. First, the size of nanoparticles can be tailored to meet a size range appropriate for lymphatic migration. In addition, functionalized nanoparticles can target cells of interest for delivery of drugs or imaging probes. Existing lymph node contrast agents map all lymph nodes regardless of metastasis status; however, by using nanoparticles, it is possible to selectively target lymphatic metastases. Moreover, using functionalized nanoparticles, it is possible to specifically deliver anticancer drugs to metastatic lymph nodes. In this review, we introduce the use of nanoparticles for lymphatic mapping, in particular highlighting design considerations for detecting metastatic lymph nodes. Furthermore, we assess trends in lymph node-targeting nanoparticles in clinical practice and suggest future directions for lymph node-targeting nanoparticles.https://www.mdpi.com/1999-4923/15/2/565lymphatic deliverynanoparticlescancer therapycancer metastasis |
| spellingShingle | Jaeseong Lee Sungtaek Kang Hyeseon Park Jeong Gil Sun Eun Chae Kim Gayong Shim Nanoparticles for Lymph Node-Directed Delivery Pharmaceutics lymphatic delivery nanoparticles cancer therapy cancer metastasis |
| title | Nanoparticles for Lymph Node-Directed Delivery |
| title_full | Nanoparticles for Lymph Node-Directed Delivery |
| title_fullStr | Nanoparticles for Lymph Node-Directed Delivery |
| title_full_unstemmed | Nanoparticles for Lymph Node-Directed Delivery |
| title_short | Nanoparticles for Lymph Node-Directed Delivery |
| title_sort | nanoparticles for lymph node directed delivery |
| topic | lymphatic delivery nanoparticles cancer therapy cancer metastasis |
| url | https://www.mdpi.com/1999-4923/15/2/565 |
| work_keys_str_mv | AT jaeseonglee nanoparticlesforlymphnodedirecteddelivery AT sungtaekkang nanoparticlesforlymphnodedirecteddelivery AT hyeseonpark nanoparticlesforlymphnodedirecteddelivery AT jeonggilsun nanoparticlesforlymphnodedirecteddelivery AT eunchaekim nanoparticlesforlymphnodedirecteddelivery AT gayongshim nanoparticlesforlymphnodedirecteddelivery |